. . "Cor et Vasa" . "Antagonist\u00E9 aldosteronov\u00FDch receptor\u016F v l\u00E9\u010Db\u011B chronick\u00E9ho srde\u010Dn\u00EDho selh\u00E1n\u00ED V\u00FDsledky nov\u00E9 studie EMPHASIS-HF"@cs . . . . . "Aldosterone antagonists play an important role in the treatment of NYHA class III and IV chronic heart failure, as shown by the RALES trial in the case of spironolactone. Aldosterone antagonists are also eff ective in treating patients after acute myocardial infarction and heart failure, as demonstrated by the EPHESUS trial for eplerenone. Recent trials have shown spironolactone to signifi cantly improve left ventricular remodeling and left ventricular diastolic function in stage I and II chronic heart failure."@en . "CZ - \u010Cesk\u00E1 republika" . . "Antagonist\u00E9 aldosteronu maj\u00ED nezastupitelnou \u00FAlohu v l\u00E9\u010Db\u011B chronick\u00E9ho srde\u010Dn\u00EDho selh\u00E1n\u00ED stadia NYHA III a IV, jak to prok\u00E1zala studie RALES pro spironolacton. Jsou tak\u00E9 \u00FA\u010Dinn\u00ED v l\u00E9\u010Db\u011B pacient\u016F s akutn\u00EDm infarktem myokardu a srde\u010Dn\u00EDm selh\u00E1n\u00EDm, jak to prok\u00E1zala studie EPHESUS pro eplerenon. Nov\u00E9 studie uk\u00E1zaly, \u017Ee spironolacton v\u00FDznamn\u011B zlep\u0161uje remodelaci lev\u00E9 komory a jej\u00ED diastolickou funkci u chronick\u00E9ho srde\u010Dn\u00EDho selh\u00E1n\u00ED stadia I a\u017E II."@cs . . "3" . "Widimsk\u00FD, Ji\u0159\u00ED" . "N" . "Aldosterone antagonists in the treatment of chronic heart failure. Results of the recent EMPHASIS-HF trial"@en . "Antagonist\u00E9 aldosteronov\u00FDch receptor\u016F v l\u00E9\u010Db\u011B chronick\u00E9ho srde\u010Dn\u00EDho selh\u00E1n\u00ED V\u00FDsledky nov\u00E9 studie EMPHASIS-HF" . "0010-8650" . "Antagonist\u00E9 aldosteronov\u00FDch receptor\u016F v l\u00E9\u010Db\u011B chronick\u00E9ho srde\u010Dn\u00EDho selh\u00E1n\u00ED V\u00FDsledky nov\u00E9 studie EMPHASIS-HF" . "186370" . "RIV/00023001:_____/11:00002649" . "Antagonist\u00E9 aldosteronov\u00FDch receptor\u016F v l\u00E9\u010Db\u011B chronick\u00E9ho srde\u010Dn\u00EDho selh\u00E1n\u00ED V\u00FDsledky nov\u00E9 studie EMPHASIS-HF"@cs . "[CD4D540032A2]" . . . . "1"^^ . "53" . "Aldosterone antagonists in the treatment of chronic heart failure. Results of the recent EMPHASIS-HF trial"@en . "Antagonist\u00E9 aldosteronu maj\u00ED nezastupitelnou \u00FAlohu v l\u00E9\u010Db\u011B chronick\u00E9ho srde\u010Dn\u00EDho selh\u00E1n\u00ED stadia NYHA III a IV, jak to prok\u00E1zala studie RALES pro spironolacton. Jsou tak\u00E9 \u00FA\u010Dinn\u00ED v l\u00E9\u010Db\u011B pacient\u016F s akutn\u00EDm infarktem myokardu a srde\u010Dn\u00EDm selh\u00E1n\u00EDm, jak to prok\u00E1zala studie EPHESUS pro eplerenon. Nov\u00E9 studie uk\u00E1zaly, \u017Ee spironolacton v\u00FDznamn\u011B zlep\u0161uje remodelaci lev\u00E9 komory a jej\u00ED diastolickou funkci u chronick\u00E9ho srde\u010Dn\u00EDho selh\u00E1n\u00ED stadia I a\u017E II." . "1"^^ . . "EMPHASIS-HF; Eplerenone; Mild chronic heart failure"@en . . "6"^^ . . "RIV/00023001:_____/11:00002649!RIV12-MZ0-00023001" . .